Biotech | May 13, 2022
Neurocrine Biosciences receives Orphan Drug Designation for Valbenazine
The treatment of chorea associated with HD is within the scope of this Orphan Drug Designation
The treatment of chorea associated with HD is within the scope of this Orphan Drug Designation
Olumiant is the first and only JAK inhibitor USFDA-approved for the treatment of Covid-19
The unit is an oral manufacturing facility at Jedcherla, Hyderabad
ASC22 (Envafolimab) is a subcutaneously administered single-domain antibody against PD-L1 and has the potential to restore virus-specific immune responses in patients with chronic viral infection
This ANDA has been co-developed in partnership with Orbicular Pharmaceutical Technologies
The partners also aim to expand their work to Latin America for the first time
Bora establishes a leadership position in Taiwan's CDMO sector as it continues to expand into the global CDMO market
Glenmark's current portfolio consists of 174 products authorized for distribution in the U.S. marketplace and 48 ANDA's pending approval with the USFDA
The plan is to advance innovative therapies to drug-resistant cancers
Novel approach driven by GN Corp Japan with potentials in neurological illnesses
Subscribe To Our Newsletter & Stay Updated
